Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Four Years of Real-World Experience in More Than 300,000 Patients and Over 60 Countries1 THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States.

AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES

Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Amgen (AMGN) This Earnings Season?

Drugmaker Amgen Inc said on Monday that it let go about 300 U.S. employees or about 1.2% of its total workforce, citing recent organizational changes to its commercial team.

Drugmaker Amgen lays off 300 U.S. employees

THOUSAND OAKS, Calif. , Jan. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Horizon Pharma

Opiant Pharmaceuticals

Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP

Intel

Verizon

Walgreens

The start of the year is a good time to add to your existing portfolio or start new positions. An excellent source to look for ideas is among the Dogs of the Dow.

Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors

AbbVie

These dividend stocks can deliver both downside protection and capital appreciation.

2 Top Passive-Income Stocks to Own in 2023

Citigroup

Southern Company

Look for the top companies in businesses the world perpetually needs.

3 Dividend Stocks You Can Safely Hold for Years

Boeing

General Dynamics

Johnson & Johnson

Kimberly-Clark

Kenvue

L3Harris

Lockheed Martin

Altria

Merck

Northrop Grumman

Philip Morris

Raytheon Technologies

Investing in blue-chip companies that pay dividends and relentlessly focusing on reinvesting the proceeds is a proven strategy for reliable long-term returns. But what about the occasional black swan? Potentially devastating litigation? Overlooked liabilities on the balance sheet? Financial engineering?

Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence

Acquiring ChemoCentryx gave them TAVNEOS, the only approved drug for the rare autoantibody-associated vasculitis. A much bigger deal for Horizon Therapeutics brought in blockbuster TEPEZZA and 11 other approved drugs.

Amgen Reinforcing Its Portfolio

AMGN has been able to grow dividends at a rate of 11% over the past 5 years, even as the stock has gained 46% over this period. It looks set to continue growing dividends thanks to its strong balance sheet, focus on organic growth and acquisitions, and capital allocation strategy.

Amgen: Dividend Growth Secure But Keep An Eye On Debt, Margins

Broadcom

Cisco Systems

Chevron

Medtronic

Morgan Stanley

Pfizer

PNC Financial Services

Pioneer Natural Resources

U.S. Bancorp

Vanguard High Dividend Yield ETF

Exxon Mobil

There are 15 stocks on my high yield watchlist for January 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory.

High Yield Stock Watchlist - January 2023

Biogen

BioNTech SE

CSL Ltd

Gilead Sciences

Moderna

Repligen

Vertex Pharmaceuticals

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.

Ranking The 10 Largest Biotechs By Pipeline

Amgen Inc. (NASDAQ:AMGN ) JP Morgan 41st Annual Healthcare Conference Call January 9, 2023 6:45 PM ET Company Participants Bob Bradway - Chairman & Chief Executive Officer Conference Call Participants Christopher Schott - JP Morgan Christopher Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be introducing Amgen today.

Amgen Inc. (AMGN) JP Morgan 41st Annual Healthcare Conference (Transcript)

Archer-Daniels-Midland Company

Aflac

Allegion

Becton, Dickinson and Co.

Dover

Con Ed

Emerson Electric

W.W. Grainger

Kraft Heinz

Coca-Cola

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

Southern Co 5.25 % Notes 2017-01.12.77 Global Series 2017B

T. Rowe Price Group

Trane Technologies plc

Dividend investing can work over time and anyone can create an ever growing passive income stream. My year over year progress is moving at a nice clip.

Dividend Income Update: December 2022

AstraZeneca

Bristol-Myers

Eli Lilly

Novo Nordisk

Novartis

Roche Holding AG

Sanofi

The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.

Ranking The Top 10 Pharmaceuticals By Pipeline

JPMorgan Chase & Co

Not only did they outpace the market, but they delivered positive gains!

Dogs Of The Dow 2023: 10 Blue-Chip Bargains

News for Amgen Stock (AMGN)